Updated Jul 16, 2026
Lechleider Robert has filed 2 SEC Form 4 filings across 1 company in the last 90 days — active on both sides. Lifetime open-market purchases: $150K. Lifetime open-market sales: $2.34M.
Robert Lechleider is the Chief Medical Officer at Immunome Inc., a biopharmaceutical company focused on developing antibody therapeutics. He has been involved in the company's efforts to leverage a proprietary human memory B cell platform for innovative treatments.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-07 | IMNM | Immunome Inc. | S — Open-market sale | 16.1K | $23.44 | $377K |
| 2026-07-07 | IMNM | Immunome Inc. | S — Open-market sale | 16.2K | $22.76 | $369K |
| 2026-07-07 | IMNM | Immunome Inc. | S — Open-market sale | 22.7K | $21.95 | $499K |
| 2026-07-07 | IMNM | Immunome Inc. | M — Option exercise | 55.0K | $8.73 | $480K |
| 2026-06-29 | IMNM | Immunome Inc. | S — Open-market sale | 14.4K | $20.66 | $298K |
| 2026-06-29 | IMNM | Immunome Inc. | S — Open-market sale | 40.6K | $19.56 | $794K |
| 2026-06-29 | IMNM | Immunome Inc. | M — Option exercise | 55.0K | $8.73 | $480K |
| 2024-11-25 | IMNM | Immunome Inc. | P — Open-market purchase | 15.8K | $9.48 | $150K |
Robert Lechleider is the Chief Medical Officer at Immunome Inc., a biopharmaceutical company focused on developing antibody therapeutics. He has been involved in the company's efforts to leverage a proprietary human memory B cell platform for innovative treatments.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 1 open-market purchases ($150K) and 5 open-market sales ($2.34M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Lechleider Robert profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.